Jeffrey R. Marks - Publications

Affiliations: 
Duke University, Durham, NC 
Area:
Molecular Biology

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, et al. LncRNA CamK-A Regulates Ca-Signaling-Mediated Tumor Microenvironment Remodeling. Molecular Cell. 72: 601. PMID 30388414 DOI: 10.1016/j.molcel.2018.10.024  0.36
2018 Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, et al. LncRNA CamK-A Regulates Ca-Signaling-Mediated Tumor Microenvironment Remodeling. Molecular Cell. PMID 30220561 DOI: 10.1016/j.molcel.2018.08.014  0.36
2017 Zheng X, Han H, Liu GP, Ma YX, Pan RL, Sang LJ, Li RH, Yang LJ, Marks JR, Wang W, Lin A. LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. The Embo Journal. PMID 28963395 DOI: 10.15252/embj.201797609  0.36
2016 Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27197300 DOI: 10.1158/1055-9965.EPI-15-1221  0.52
2016 Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH. Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Molecular Systems Biology. 12: 860. PMID 26969729 DOI: 10.15252/msb.20156506  0.52
2016 Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. Journal of the National Cancer Institute. 108. PMID 26683405 DOI: 10.1093/jnci/djv372  0.52
2015 Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, ... ... Marks JR, et al. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Research : Bcr. 17: 128. PMID 26384318 DOI: 10.1186/s13058-015-0630-z  0.52
2015 Siamakpour-Reihani S, Owzar K, Jiang C, Turner T, Deng Y, Bean SM, Horton JK, Berchuck A, Marks JR, Dewhirst MW, Secord AA. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecologic Oncology. PMID 26260910 DOI: 10.1016/j.ygyno.2015.08.001  0.52
2015 Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 435-41. PMID 25471344 DOI: 10.1158/1055-9965.EPI-14-1178  0.52
2014 Tang X, Lin CC, Spasojevic I, Iversen ES, Chi JT, Marks JR. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Research : Bcr. 16: 415. PMID 25091696 DOI: 10.1186/s13058-014-0415-9  0.52
2013 Marks JR. Refining the role of BRCA1 in combating oxidative stress. Breast Cancer Research : Bcr. 15: 320. PMID 24314328 DOI: 10.1186/bcr3583  0.52
2013 Schildkraut JM, Iversen ES, Akushevich L, Whitaker R, Bentley RC, Berchuck A, Marks JR. Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1709-21. PMID 23917454 DOI: 10.1158/1055-9965.EPI-13-0192  0.52
2013 Jin H, Daly DS, Marks JR, Zangar RC. Oxidatively modified proteins as plasma biomarkers in breast cancer. Cancer Biomarkers : Section a of Disease Markers. 13: 193-200. PMID 23912491 DOI: 10.3233/CBM-130349  0.52
2013 Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, Marks JR, Berchuck A. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecologic Oncology. 129: 159-64. PMID 23274563 DOI: 10.1016/j.ygyno.2012.12.030  0.52
2013 Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, Berchuck A, Schildkraut JM. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecologic Oncology. 129: 173-8. PMID 23262379 DOI: 10.1016/j.ygyno.2012.12.027  0.52
2012 Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 9-14. PMID 22193641 DOI: 10.1097/IGC.0b013e318231f140  0.52
2012 Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517-525)) Journal of Clinical Oncology. 30: 678. DOI: 10.1200/JCO.2012.42.0331  0.52
2011 Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. Plos Genetics. 7: e1002229. PMID 21852960 DOI: 10.1371/journal.pgen.1002229  0.52
2011 Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research : Bcr. 13: R62. PMID 21672245 DOI: 10.1186/bcr2899  0.52
2011 Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1543-51. PMID 21586622 DOI: 10.1158/1055-9965.EPI-10-1248  0.52
2011 Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochemical Pharmacology. 82: 122-30. PMID 21501600 DOI: 10.1016/j.bcp.2011.03.031  0.52
2011 Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA. Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor. Molecular Endocrinology (Baltimore, Md.). 25: 867-76. PMID 21393447 DOI: 10.1210/me.2010-0277  0.52
2011 Havrilesky LJ, Sanders GD, Kulasingam S, Chino JP, Berchuck A, Marks JR, Myers ER. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer. 117: 545-53. PMID 21254049 DOI: 10.1002/cncr.25624  0.52
2011 Liggett TE, Melnikov AA, Marks JR, Levenson VV. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. International Journal of Cancer. Journal International Du Cancer. 128: 492-9. PMID 20473856 DOI: 10.1002/ijc.25363  0.52
2010 Adam MA, Untch BR, Danko ME, Stinnett S, Dixit D, Koh J, Marks JR, Olson JA. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 95: 4917-24. PMID 20685860 DOI: 10.1210/jc.2010-0666  0.52
2010 Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, Murphy SK, Iversen E, Marks JR, Berchuck A. Expression signatures of TP53 mutations in serous ovarian cancers. Bmc Cancer. 10: 237. PMID 20504346 DOI: 10.1186/1471-2407-10-237  0.52
2010 Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA. Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. Journal of the American College of Surgeons. 210: 797-805.e1, 805-7. PMID 20421053 DOI: 10.1016/j.jamcollsurg.2010.02.045  0.52
2010 Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. Plos One. 5: e10061. PMID 20386703 DOI: 10.1371/journal.pone.0010061  0.52
2010 Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment. 124: 441-51. PMID 20309627 DOI: 10.1007/s10549-010-0842-y  0.52
2010 Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, ... ... Marks JR, et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 600-4. PMID 20142253 DOI: 10.1158/1055-9965.EPI-09-0861  0.52
2010 Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecologic Oncology. 116: 556-62. PMID 20006900 DOI: 10.1016/j.ygyno.2009.11.020  0.52
2010 Hoyo C, Schildkraut JM, Murph SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingeart B, Mayne S, Fraumeni J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas (International Journal of Cancer (2009) 125, (2673-2678)) International Journal of Cancer. 126: 799. DOI: 10.1002/ijc.24975  0.52
2009 Hoyo C, Grubber J, Demark-Wahnefried W, Lobaugh B, Jeffreys AS, Grambow SC, Marks JR, Keku TO, Walther PJ, Schildkraut JM. Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men. Journal of the National Medical Association. 101: 711-6. PMID 19634593  0.52
2009 Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Calingeart B, Mayne S, Fraumeni J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. International Journal of Cancer. Journal International Du Cancer. 125: 2673-8. PMID 19626700 DOI: 10.1002/ijc.24623  0.52
2009 Westmoreland TJ, Wickramasekara SM, Guo AY, Selim AL, Winsor TS, Greenleaf AL, Blackwell KL, Olson JA, Marks JR, Bennett CB. Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. Plos One. 4: e5830. PMID 19503795 DOI: 10.1371/journal.pone.0005830  0.52
2009 Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY. Do serum biomarkers really measure breast cancer? Bmc Cancer. 9: 164. PMID 19476629 DOI: 10.1186/1471-2407-9-164  0.52
2009 Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Role of eotaxin-1 signaling in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2647-56. PMID 19351767 DOI: 10.1158/1078-0432.CCR-08-2024  0.52
2009 Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2448-55. PMID 19318476 DOI: 10.1158/1078-0432.CCR-08-2430  0.52
2009 Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 69: 2349-57. PMID 19276375 DOI: 10.1158/0008-5472.CAN-08-2902  0.52
2009 Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Research and Treatment. 118: 635-43. PMID 19224362 DOI: 10.1007/s10549-008-0301-1  0.52
2009 Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Molecular Cancer Research : McR. 7: 199-209. PMID 19208741 DOI: 10.1158/1541-7786.MCR-08-0314  0.52
2009 Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 28: 209-18. PMID 18836486 DOI: 10.1038/onc.2008.374  0.52
2008 Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3324-30. PMID 18612148 DOI: 10.1200/JCO.2007.14.2471  0.52
2008 Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF. ISG15 as a novel tumor biomarker for drug sensitivity. Molecular Cancer Therapeutics. 7: 1430-9. PMID 18566215 DOI: 10.1158/1535-7163.MCT-07-2345  0.52
2008 Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Research : Bcr. 10: R45. PMID 18474099 DOI: 10.1186/bcr2096  0.52
2008 Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 585-93. PMID 18349276 DOI: 10.1158/1055-9965.EPI-07-0596  0.52
2008 Bennett CB, Westmoreland TJ, Verrier CS, Blanchette CA, Sabin TL, Phatnani HP, Mishina YV, Huper G, Selim AL, Madison ER, Bailey DD, Falae AI, Galli A, Olson JA, Greenleaf AL, ... Marks JR, et al. Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. Plos One. 3: e1448. PMID 18197258 DOI: 10.1371/journal.pone.0001448  0.52
2008 Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. Plos One. 3: e1373. PMID 18167534 DOI: 10.1371/journal.pone.0001373  0.52
2007 Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. Journal of the National Medical Association. 99: 718-22. PMID 17668637  0.52
2007 Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, ... ... Marks JR, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 67: 3027-35. PMID 17409409 DOI: 10.1158/0008-5472.CAN-06-3261  0.52
2007 Huper G, Marks JR. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Research. 67: 2990-3001. PMID 17409405 DOI: 10.1158/0008-5472.CAN-06-4065  0.52
2007 Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 473-80. PMID 17372242 DOI: 10.1158/1055-9965.EPI-06-0868  0.52
2007 Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 334-41. PMID 17301268 DOI: 10.1158/1055-9965.EPI-06-0681  0.52
2007 Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecologic Oncology. 105: 312-20. PMID 17276500 DOI: 10.1016/j.ygyno.2006.12.017  0.52
2007 Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of Clinical Investigation. 117: 206-17. PMID 17160136 DOI: 10.1172/JCI29293  0.52
2007 Jesneck JL, Mukherjee S, Nolte LW, Lokshin AE, Marks JR, Lo J. Decision fusion of circulating markers for breast cancer detection in premenopausal women Proceedings of the 7th Ieee International Conference On Bioinformatics and Bioengineering, Bibe. 1434-1438. DOI: 10.1109/BIBE.2007.4375762  0.52
2006 Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 16: 1733-45. PMID 17009964 DOI: 10.1111/j.1525-1438.2006.00660.x  0.52
2006 Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels International Journal of Gynecological Cancer. 16: 1529-1535. PMID 16884361 DOI: 10.1111/j.1525-1438.2006.00623.x  0.52
2006 Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan C, Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Research. 66: 4065-78. PMID 16618726 DOI: 10.1158/0008-5472.CAN-05-4083  0.52
2006 Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Molecular Cancer Research : McR. 4: 283-92. PMID 16603642 DOI: 10.1158/1541-7786.MCR-05-0138  0.52
2006 Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR, Berchuck A. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecologic Oncology. 101: 390-7. PMID 16551475 DOI: 10.1016/j.ygyno.2006.02.014  0.52
2006 Schafer ZT, Parrish AB, Wright KM, Margolis SS, Marks JR, Deshmukh M, Kornbluth S. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Research. 66: 2210-8. PMID 16489023 DOI: 10.1158/0008-5472.CAN-05-3923  0.52
2006 Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Research. 34: 555-63. PMID 16432260 DOI: 10.1093/nar/gkj468  0.52
2006 Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology (Cambridge, Mass.). 17: 104-7. PMID 16357602 DOI: 10.1097/01.ede.0000190538.55645.f8  0.52
2006 Brown NM, Stenzel TT, Friedman PN, Henslee J, Huper G, Marks JR. Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Research and Treatment. 97: 41-7. PMID 16319979 DOI: 10.1007/s10549-005-9085-8  0.52
2006 Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439: 353-7. PMID 16273092 DOI: 10.1038/nature04296  0.52
2005 Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6117-25. PMID 16087946 DOI: 10.1200/JCO.2005.06.075  0.52
2005 Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3686-96. PMID 15897565 DOI: 10.1158/1078-0432.CCR-04-2398  0.52
2005 Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecologic Oncology. 97: 543-9. PMID 15863158 DOI: 10.1016/j.ygyno.2005.01.025  0.52
2005 Wang W, Huper G, Guo Y, Murphy SK, Olson JA, Marks JR. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene. 24: 2705-14. PMID 15735726 DOI: 10.1038/sj.onc.1208464  0.52
2005 Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ. IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 403-8. PMID 15734965 DOI: 10.1158/1055-9965.EPI-04-0426  0.52
2005 Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR, Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology. 96: 355-61. PMID 15661221 DOI: 10.1016/j.ygyno.2004.10.012  0.52
2004 Wang W, Nahta R, Huper G, Marks JR. TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Molecular Cancer Research : McR. 2: 442-52. PMID 15328371  0.52
2004 Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, Sampson JH, Gromeier M. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4831-8. PMID 15269159 DOI: 10.1158/1078-0432.CCR-03-0694  0.52
2004 Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. American Journal of Obstetrics and Gynecology. 190: 910-25. PMID 15118612 DOI: 10.1016/j.ajog.2004.02.005  0.52
2004 Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and Cellular Biology. 24: 3992-4003. PMID 15082792 DOI: 10.1128/MCB.24.9.3992-4003.2004  0.52
2004 Westmoreland TJ, Marks JR, Olson JA, Thompson EM, Resnick MA, Bennett CB. Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryotic Cell. 3: 430-46. PMID 15075273 DOI: 10.1128/EC.3.2.430-446.2004  0.52
2004 Tebbit CL, Bentley RC, Olson JA, Marks JR. Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes, Chromosomes & Cancer. 40: 51-4. PMID 15034868 DOI: 10.1002/gcc.20017  0.52
2004 Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A. Gene expression patterns that characterize advanced stage serous ovarian cancers. Journal of the Society For Gynecologic Investigation. 11: 51-9. PMID 14706684 DOI: 10.1016/j.jsgi.2003.07.004  0.52
2003 Westmoreland TJ, Olson JA, Saito WY, Huper G, Marks JR, Bennett CB. Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast. The Journal of Surgical Research. 113: 62-73. PMID 12943812 DOI: 10.1016/S0022-4804(03)00155-0  0.52
2003 Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A, Peng Y, Pei L, Marks JR, Lowe S, Hoey T, et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 3: 297-302. PMID 12676587 DOI: 10.1016/S1535-6108(03)00054-0  0.52
2003 Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 12: 226-7. PMID 12646513  0.52
2002 Spang R, Zuzan H, West M, Nevins J, Blanchette C, Marks JR. Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biology. 2: 369-81. PMID 12542420  0.52
2002 Gilliam LK, Lobenhofer EK, Greer PK, Scearce RM, Cirisano FD, Marks JR, Hale LP. BRCA2 monoclonal antibodies react with differentiating epithelium. Hybridoma and Hybridomics. 21: 261-9. PMID 12193279 DOI: 10.1089/153685902760213877  0.52
2002 Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nature Genetics. 31: 133-4. PMID 12021784 DOI: 10.1038/ng888  0.52
2001 Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecologic Oncology. 83: 491-500. PMID 11733961 DOI: 10.1006/gyno.2001.6464  0.52
2001 West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 98: 11462-7. PMID 11562467 DOI: 10.1073/pnas.201162998  0.52
2001 Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 98: 9796-801. PMID 11481438 DOI: 10.1073/pnas.171138398  0.52
2001 Moorman PG, Hamza A, Marks JR, Olson JA. Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative breast carcinoma. Cancer. 91: 2258-62. PMID 11413513 DOI: 10.1002/1097-0142(20010615)91:12<2258::AID-CNCR1256>3.0.CO;2-V  0.52
2001 Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. Journal of the Society For Gynecologic Investigation. 8: 104-13. PMID 11336882 DOI: 10.1016/S1071-5576(01)00093-4  0.52
2000 Lobenhofer EK, Marks JR. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. The Journal of Steroid Biochemistry and Molecular Biology. 75: 11-20. PMID 11179904 DOI: 10.1016/S0960-0760(00)00132-1  0.52
2000 Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 97: 6049-54. PMID 10811911 DOI: 10.1073/pnas.100566997  0.52
2000 Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 99-110. PMID 10714766  0.52
1999 Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Managing hereditary ovarian cancer risk. Cancer. 86: 2517-24. PMID 10630177 DOI: 10.1002/(SICI)1097-0142(19991201)86:11+<2517::AID-CNCR8>3.0.CO;2-B  0.52
1999 Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Isolation and initial characterization of the BRCA2 promoter. Oncogene. 18: 6000-12. PMID 10557089 DOI: 10.1038/sj.onc.1202990  0.52
1999 Lambers AR, Gumbs C, Ali S, Marks JR, Iglehart JD, Berchuck A, Futreal PA. Bcl10 is not a target for frequent mutation in human carcinomas. British Journal of Cancer. 80: 1575-6. PMID 10408401 DOI: 10.1038/sj.bjc.6690564  0.52
1998 Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cellular Immunology. 190: 141-55. PMID 9878115 DOI: 10.1006/cimm.1998.1390  0.52
1998 Burke HB, Hoang A, Iglehart JD, Marks JR. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer. 82: 874-7. PMID 9486576 DOI: 10.1002/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y  0.52
1997 Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell FE, Marks JR, Winchester DP, Bostwick DG. Artificial neural networks improve the accuracy of cancer survival prediction Cancer. 79: 857-862. PMID 9024725 DOI: 10.1002/(SICI)1097-0142(19970215)79:4<857::AID-CNCR24>3.0.CO;2-Y  0.52
1996 Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Research. 24: 4558-64. PMID 8948649 DOI: 10.1093/nar/24.22.4558  0.52
1996 Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer Molecular Carcinogenesis. 17: 160-162. PMID 8944076 DOI: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J  0.52
1996 Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A. p53 overexpression in advanced-stage endometrial adenocarcinoma American Journal of Obstetrics and Gynecology. 175: 1246-1252. PMID 8942496 DOI: 10.1016/S0002-9378(96)70036-4  0.52
1996 Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Role of BRCA1 mutation screening in the management of familial ovarian cancer American Journal of Obstetrics and Gynecology. 175: 738-746. PMID 8828444 DOI: 10.1053/OB.1996.V175.A74288  0.52
1995 Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proceedings of the National Academy of Sciences of the United States of America. 92: 8338-42. PMID 7667291 DOI: 10.1073/pnas.92.18.8338  0.52
1995 Iglehart JD, Kerns BJ, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer Breast Cancer Research and Treatment. 34: 253-263. PMID 7579490 DOI: 10.1007/BF00689717  0.52
1994 Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJM, Iglehart JD. Overexpression of p53 and HER-2/ neu proteins as prognostic markers in early stage breast cancer Annals of Surgery. 219: 332-341. PMID 7909221 DOI: 10.1097/00000658-199404000-00002  0.52
1994 Lightner VA, Marks JR, Mccachren SS. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue Experimental Cell Research. 210: 177-184. PMID 7507849 DOI: 10.1006/excr.1994.1027  0.52
1993 Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer Journal of the National Cancer Institute. 85: 1513-1519. PMID 8360934 DOI: 10.1093/jnci/85.18.1513  0.52
1993 Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive Production of Macrophage Colony-Stimulating Factor and Interleukin-6 by Human Ovarian Surface Epithelial Cells Experimental Cell Research. 207: 332-339. PMID 8344385 DOI: 10.1006/excr.1993.1200  0.52
1992 Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 40: 1047-51. PMID 1607637 DOI: 10.1177/40.7.1607637  0.52
1992 Huper G, Marks JR, Wiener JR, Iglehart JD. Relative promoter activity in human mammary epithellal cells assayed by transient expression In Vitro Cellular and Developmental Biology - Animal. 28: 730-734. PMID 1483964 DOI: 10.1007/BF02631061  0.52
1992 Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, Humphrey P, Berchuck A, Ponder BAJ, Bast RC. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and x-chromosome inactivation Journal of the National Cancer Institute. 84: 1793-1798. PMID 1433368 DOI: 10.1093/jnci/84.23.1793  0.52
1992 Davidoff AM, Dirk Iglehart J, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers Proceedings of the National Academy of Sciences of the United States of America. 89: 3439-3442. PMID 1373500 DOI: 10.1073/pnas.89.8.3439  0.52
1991 Davidoff AM, Humphrey PA, Dirk Iglehart J, Marks JR. Genetic basis for p53 overexpression in human breast cancer Proceedings of the National Academy of Sciences of the United States of America. 88: 5006-5010. PMID 2052583 DOI: 10.1073/pnas.88.11.5006  0.52
1991 Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. p53 alterations in all stages of breast cancer. Journal of Surgical Oncology. 48: 260-7. PMID 1745051  0.52
1991 Pence JC, Kizilbash AM, Kerns BJ, Marks JR, Iglehart JD. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. Journal of Surgical Oncology. 48: 11-20. PMID 1716331  0.52
Show low-probability matches.